Citylights

• Research type

  Research Study

• Full title

  A Phase 2a double blind, randomized, parallel arm, placebo-controlled trial to investigate the effects of two dose levels of CIT-013 on disease activity in patients with Hidradenitis Suppurativa (HS)

• IRAS ID

  1012320

• Contact name

  Maarten Kraan

• Contact email

  mkraan@citryll.com

• Sponsor organisation

  Citryll BV

• Eudract number

  2025-521684-12

• Clinicaltrials.gov Identifier

  NCT06993233

• Research summary

  The safety and efficacy of a new antibody in different strenghts in patients suffering from Hidradenitis Suppurativa, a condition that causes small, painful lumps to form under the skin, is investigated. The antibody will be injected and it is investigated which side effects can occur. From tests in animals and cell culture, no severe side effects are expected. Participants may receive verum (antibody) or a placebo (a substance that looks like the verum, but does not contain the antibody).

• REC name

  East of Scotland Research Ethics Service REC 2

• REC reference

  25/ES/0054

• Date of REC Opinion

  8 Aug 2025

• REC opinion

  Further Information Favourable Opinion